Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors - LIGHT

Study identifier:RDEA594-303

ClinicalTrials.gov identifier:NCT01508702

EudraCT identifier:2011-003756-39

CTIS identifier:N/A

Study Complete

Official Title

A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled Study to Assess the Efficacy and Safety of Lesinurad Monotherapy Compared to Placebo in Subjects with Gout and an Intolerance or Contraindication to a Xanthine Oxidase Inhibitor

Medical condition

Gout

Phase

Phase 3

Healthy volunteers

No

Study drug

lesinurad, Placebo

Sex

All

Actual enrollment

214

Study type

Interventional

Age

18 Years - 85 Years

Date

Study Start Date: 01 Jan 2012
Primary Completion Date: 01 Oct 2013
Study Completion Date: 01 Nov 2013

Study design

Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment

Verification:

Verified 01 Jul 2015 by Ardea Biosciences, Inc.

Sponsors

Ardea Biosciences, Inc.

Collaborators

-

Inclusion and exclusion criteria